EpiVax has developed comprehensive analytical capabilities in the field of computational immunology.

We are dedicated to applying our tools to reengineering therapeutic proteins and to designing new vaccines.

We leverage our tools and expertise adding value to our clients’ research and development efforts while we apply them to our own pipeline of therapeutic proteins and vaccine candidates.

We have extensive immunology and microbiology laboratory capabilities including the most sophisticated MHC binding assays on the market.

Because our assays utilize highly purified recombinant soluble class I and class II MHC molecules rather than whole cells or lysates, we can achieve the greatest level of specificity and sensitivity.

EpiVax knows the scientific, financial, and regulatory challenges faced by today’s pharmaceutical industry and applies this know-how at every step from design to execution to IND.